Amelioration of polycystic ovary syndrome-related disorders by supplementation of thymoquinone and metformin

Table 5 Comparison of the serum SOD activity and MDA between the two studied groups

		At the beginning of the study	After 3 months	After 6 months	P1	P2	P3
Serum SOD activity (U/mg protein)	Group A	44.36 ± 14.26	52.31 ± 14.2	60.27 ± 12.22	0.005*	0.00**	0.00**
	Group B	44.25 ± 19.37	60.16 ± 13.8	76.08 ± 8.38	0.00**	0.00**	0.00**
	P	0.98	0.00**	0.00**
MDA (μmol/l)	Group A	0.31 ± 0.03	0.29 ± 0.03	0.26 ± 0.02	0.15	0.0004**	0.03*
	Group B	0.32 ± 0.04	0.26 ± 0.02	0.23 ± 0.03	0.0002**	0.00**	0.03*
	P	0.52	0.03*	0.03*

*Statistically significant
**Highly significant (≤ 0.001)
P1, beginning of the study compared to after 3 months; P2, beginning of the study compared to after 6 months; P3, after 3 months compared to after 6 months